Drug Profile
Avenciguat - Boehringer Ingelheim
Alternative Names: BI-685509Latest Information Update: 11 Mar 2024
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Skin disorder therapies; Urologics
- Mechanism of Action Soluble guanylyl cyclase agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diabetic nephropathies; Portal hypertension; Renal failure; Systemic scleroderma
Most Recent Events
- 05 Mar 2024 Boehringer Ingelheim plans a phase I pharmacokinetic trial in patients with Liver disorders in March 2024 (NCT06272058)
- 16 Jan 2024 Boehringer Ingelheim initiates a phase I pharmacokinetic trial (In volunteers) in Germany (PO) (NCT06193811)
- 05 Jan 2024 Boehringer Ingelheim plans a phase I relative bioavailability trial (In volunteers) (PO)(NCT06193811)